Core Viewpoint - Design Therapeutics, Inc. (DSGN) has seen a 23.7% increase in share price over the past four weeks, closing at $5.01, with a potential upside of 39.7% based on Wall Street analysts' mean price target of $7 [1] Price Targets - The average price target consists of three short-term estimates ranging from a low of $4 to a high of $12, with a standard deviation of $4.36, indicating variability among analysts [2] - The lowest estimate suggests a decline of 20.2% from the current price, while the highest estimate indicates a potential upside of 139.5% [2] Analyst Sentiment - Analysts show strong agreement regarding DSGN's ability to report better earnings than previously predicted, which supports the view of potential upside [4] - The Zacks Consensus Estimate for the current year has increased by 7.4% over the past month, with two estimates revised higher and no negative revisions [10] Zacks Rank - DSGN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating a strong potential upside [11]

Financial Performance - The company reported a net loss of $200.5 million as of June 30, 2024, with cash and cash equivalents totaling $261.0 million[65]. - The company has not generated any revenue from product sales to date[65]. - The company anticipates continued net losses and negative cash flows from operations for the foreseeable future, primarily funded through equity and debt financing[82]. - The company reported a net cash used in operating activities of $(23,699,000) for the six months ended June 30, 2024, an improvement from $(31,228,000) in the same period of 2023[86]. Research and Development - Research and development expenses for Q2 2024 were $10.516 million, a decrease of $6.548 million from $17.064 million in Q2 2023[77]. - Research and development expenses for the three months ended June 30, 2024, totaled $10,516,000, a decrease of 38.4% from $17,064,000 in the same period of 2023[78]. - Research and development expenses for the six months ended June 30, 2024, were $20,317,000, a decrease of 38.1% from $32,794,000 in the same period of 2023[80]. - The company aims to complete GLP studies for the new product candidate DT-216P2 by the end of 2024 and expects to initiate clinical trials in 2025[61]. - The company has received FDA clearance for the IND of DT-168 and plans to initiate Phase 1 development in 2024[62]. - In preclinical studies, the HD GeneTAC candidate molecules showed over 50% reduction in mutant HTT RNA and protein in an animal model[63]. - The company plans to recruit 200 patients for an observational study in FECD to confirm disease characteristics and identify rapid progression risks[62]. Operating Expenses - General and administrative expenses for Q2 2024 were $4.527 million, down by $1.005 million from $5.532 million in Q2 2023[77]. - Total operating expenses for Q2 2024 were $15.043 million, a reduction of $7.553 million compared to $22.596 million in Q2 2023[77]. - For the six months ended June 30, 2024, total operating expenses were $29,443,000, down 33.4% from $44,247,000 in the same period of 2023[79]. - General and administrative expenses for the six months ended June 30, 2024, were $9,126,000, down 20.3% from $11,453,000 in the same period of 2023[81]. Cash and Funding - As of June 30, 2024, the company had $261.0 million in cash, cash equivalents, and investment securities, a decrease of $20.8 million from $281.8 million at December 31, 2023[82]. - The company expects its existing cash and investments to be sufficient to fund planned operating expenses for more than the next 12 months[85]. - Future capital requirements will depend on various factors, including the scope and costs of clinical trials and the emergence of competing therapies[87]. - The company has not sold any shares under the $100.0 million ATM Program as of June 30, 2024, which is part of the $300.0 million shelf registration statement filed in April 2022[84]. Company Classification - The company remains classified as an emerging growth company until at least December 31, 2026, allowing it to rely on certain exemptions from public company reporting requirements[101]. - The company has irrevocably elected not to avail itself of the exemption from new or revised accounting standards, thus will adhere to the same standards as other public companies[102]. - The company will cease to be an emerging growth company upon reaching at least $1.235 billion in annual revenue or if certain market conditions are met[103].

Financial Performance - Research and development (R&D) expenses for Q2 2024 were $10.5 million, a decrease from $17.1 million in Q2 2023[4] - General and administrative (G&A) expenses for Q2 2024 were $4.5 million, down from $5.5 million in Q2 2023[4] - The net loss for Q2 2024 was $11.8 million, compared to a net loss of $19.9 million in Q2 2023[4] - Total operating expenses for Q2 2024 were $15.0 million, down from $22.6 million in Q2 2023[8] Cash Position - Cash, cash equivalents, and marketable securities totaled $261.0 million as of June 30, 2024, expected to fund operations into 2029[4] Clinical Development - The company is on track to start patient trials for DT-216P2 in Friedreich Ataxia (FA) in 2025[3] - DT-168 for Fuchs Endothelial Corneal Dystrophy (FECD) is advancing toward Phase 1 development later this year, with 200 patients to be enrolled in an observational study[3] - The company aims to complete GLP studies for DT-216P2 by year-end 2024[3] - Design Therapeutics is progressing preclinical programs for Huntington's Disease (HD) and Myotonic Dystrophy Type-1 (DM1) in anticipation of future IND submissions[3] Share Information - The weighted-average shares of common stock outstanding for Q2 2024 were approximately 56.6 million, compared to 55.9 million in Q2 2023[8]

Friedreich Ataxia (FA) and Fuchs Endothelial Corneal Dystrophy (FECD) Programs on Track and Advancing Toward Clinical Trials Active Research Pipeline with Programs Progressing in Myotonic Dystrophy Type-1 (DM1) and Huntington's Disease (HD) Cash and Securities of $261.0 Million Supports Operations Through Potentially Four Clinical Proof-of-Concept Data Sets CARLSBAD, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious ...

Friedreich Ataxia (FA) and Fuchs Endothelial Corneal Dystrophy (FECD) Programs on Track and Advancing Toward Clinical Trials Active Research Pipeline with Programs Progressing in Myotonic Dystrophy Type-1 (DM1) and Huntington's Disease (HD) Cash and Securities of $261.0 Million Supports Operations Through Potentially Four Clinical Proof-of-Concept Data Sets CARLSBAD, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40288 Design Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 82-3929248 (State or other jurisd ...

Exhibit 99.1 Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones Advancing DT-216P2, New Drug Product for Friedreich Ataxia (FA), Toward Clinical Trials Starting Phase 1 Development for Fuchs Endothelial Corneal Dystrophy (FECD) in 2024; Observational Study Currently Enrolling Patients Design Therapeutics is a biotechnology company developing a new class of therapies based on its platform of GeneTAC™ gene targeted chimera small molecules. The company ...

CARLSBAD, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat at the 2024 RBC Capital Markets Healthcare Conference on Wednesday, May 15, 2024, at 11:30 a.m. ET in New York. A live webcast of the fireside chat will be available here and in the investors section of the company's website at www.designtx.com. The webcast will ...

Design Therapeutics, Inc. (NASDAQ:DSGN) Q4 2023 Results Conference Call March 19, 2024 4:30 PM ET Company Participants Sean Jeffries - COO Pratik Shah - Chairman, CEO Conference Call Participants Joseph Schwartz - Leerink Partners Laura Chico - Wedbush Operator Good afternoon, and welcome to Design’s Conference Call. [Operator Instructions]. Please be advised that this call is being recorded at the company's request. I would now like to turn the call over to Dr. Sean Jeffries, Chief Operating Officer of De ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 10-K Washington, D.C. 20549 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40288 Design Therapeutics, Inc. (Exact name of Registrant as specified in its Charter) Delaware 82-3929248 (State or other jurisdicti ...